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Previewsstudies that will hopefully bring us to
the point that we can apply precision
medicine to the therapy of multiple
myeloma.
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Oncogenic activation of Ras proteins due tomissensemutations is frequently detected in human cancers but
rarely in breast cancer. In this issue of Cancer Cell, McLaughlin and colleagues report that ablation of the
GasGAP gene, RASAL2, is an alternative mechanism by which Ras becomes activated in breast cancer.Ras GTPases are essential components
of signaling pathways that emanate cues
from cell surface receptors to regulate
diverse cellular processes, including cell
cycle progression, cell survival, actin
cytoskeletal organization, cell polarity
and movement, as well as vesicular and
nuclear transport (Vigil et al., 2010). Ras
proteins (H-Ras, N-Ras, and K-Ras),
together with their two key regulators
(guanine nucleotide exchange factors/
GEFs and GTPase-activating proteins/
GAPs), constitute cellular binary switches
that cycle between ‘‘on’’ and ‘‘off’’ confor-
mations conferred by the loading of
GTP or GDP, respectively. The transition
between the active GTP-bound and inac-
tive GDP-bound states of Ras GTPases is
controlled by GEFs, which promote the
activation of Ras proteins by stimulatingGDP for GTP exchange, and GAPs, which
terminate the activation status by acceler-
ating Ras-mediated GTP hydrolysis (Bos
et al., 2007; Tcherkezian and Lamarche-
Vane, 2007). Ras GTPases and cancer
are tightly associated, as high frequency
of mutational activation of Ras proteins
is observed in 33% of human cancers.
The intrinsic GTP hydrolysis activity
of Ras is the predominant target of the
most common somatic mutations that
are found in the oncogenic variants
of RAS alleles (Pylayeva-Gupta et al.,
2011). Specifically, oncogenic substitu-
tion in residue G12 or G13 results in pro-
nounced attenuation of intrinsic GTP
hydrolysis, which leads to the persis-
tence of the GTP-bound state of Ras
and subsequently activates a multitude
of Ras-dependent downstream effectorpathways. Beyond Ras, hyperactivation
of GEFs and functional deregulation,
including suppression and loss-of-func-
tion mutations of GAPs, have also been
suggested to play important roles in can-
cer progression (Vigil et al., 2010).
Despite the prevalence of oncogenic
RAS mutations in human cancers, K-
RAS, H-RAS, and N-RAS are rarely
mutated in breast cancer (Karnoub and
Weinberg, 2008). Nonetheless, the Ras/
ERK pathway is hyperactivated in more
than half of breast cancers and has been
implicated in tumor progression and
recurrence (von Lintig et al., 2000), sug-
gesting that Ras proteins may be more
frequently activated by alternative mech-
anisms in this type of tumors. A new study
by McLaughlin et al. (2013) in this issue of
Cancer Cell uncovers the role of RASAL2,eptember 9, 2013 ª2013 Elsevier Inc. 277
Figure 1. Alternative Activation of Wild-Type Ras via Deregulation of RasGAPs in Human
Cancers
(A) Suppression of RASAL2 is specifically found in human luminal B breast cancer and correlates with the
hypermethylation status of RASAL2 promoter CpG sites. Loss of RASAL2 activates wild-type Ras and
promotes cancer progression and metastasis in the breast cancer xenograft model and genetically engi-
neered mouse models (McLaughlin et al., 2013).
(B) Germline mutational loss of the NF1 tumor suppressor is found in familial cancer syndrome neurofibro-
matosis type 1 and is mutated or suppressed via PKC-dependent proteasome degradation in several
sporadic cancers, including glioblastoma, non-small cell lung cancer, neuroblastoma, and melanoma
(McGillicuddy et al., 2009; Vigil et al., 2010).
(C) DAB2IP, another RasGAP, is also epigenetically silenced by EZH2 and functions as a tumor and
metastasis suppressor via activation of both Ras and NF-kB pathways in prostate cancer (Min et al.,
2010).
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as a tumor suppressor in breast cancer
through direct blockage of Ras activation.
They found that RASAL2 is frequently
absent or minimally expressed in cells
derived from luminal breast cancer.
Reconstitution of RASAL2 in cells with
low endogenous expression suppressed
Ras-GTP and the activation of down-
stream ERK. Conversely, knockdown of
RASAL2 in normal immortalized mam-
mary epithelial cells enhanced Ras-GTP
and increased the level of phospho-
ERK. These results demonstrate that
RASAL2 is a functional RasGAP and that
its loss activates the Ras/ERK signaling
pathway.
Whereas reconstitution of RASAL2 in
RASAL2-deficient breast cancer cells in-
hibited anchorage-independent colony
growth and potently suppressed tumor
growth in vivo, it had almost no significant
effect on RASmutant tumors. The depen-
dency of Ras mutation status suggests
that the RasGAP domain in RASAL2 plays
an important role. Indeed, two RasGAP
domain mutants (K417E and K567X) that
are defective in blocking the activation278 Cancer Cell 24, September 9, 2013 ª201of Ras/ERK pathway failed to suppress
anchorage-independent cell growth, indi-
cating that the RasGAP domain is essen-
tial for the tumor suppressor function
of RASAL2. Elevated levels of K-Ras-
GTP andH-Ras-GTP significantly contrib-
uted to the pathogenesis promoted
by RASAL2 inactivation. In contrast, abla-
tion of RASAL2 enhanced cell migration
and invasion in vitro and promoted cancer
progression from ductal carcinoma in situ
(DCIS) to invasive carcinoma in a breast
cancer xenograft model using MCF10A-
DCIS cells.
The functional role of RASAL2 was
further examined by the authors in genet-
ically engineered mice lacking Rasal2.
Rasal2/mice exhibit shorter overall sur-
vival as compared to control animals.
However, Rasal2/mice did not develop
tumors, suggesting that the loss of Rasal2
itself is not sufficient to drive tumorigen-
esis in mice. Interestingly, Rasal2/
mice that crossed with MMTVneu devel-
oped substantially more metastases
than the MMTVneu mice, with higher fre-
quency and larger size of metastases,
as well as an additional spectrum of3 Elsevier Inc.distant metastases, including brain, kid-
ney, ovary, and gastrointestinal tract,
which are not observed in MMTVneu
mice. Correspondingly, the activation
of Ras/ERK and AKT were substantially
elevated in the compound mice, suggest-
ing that the loss of Rasal2 promotes
metastasis via activation of Ras. In addi-
tion, the authors also propose that
RASAL2 may play a broader tumor-sup-
pressive role in other cancer types as
the loss of Rasal2 potently promotes
metastasis in Trp53 mutant mice.
To understand the suppression mecha-
nism of RASAL2 in human breast cancers,
McLaughlin et al. (2013) examined the
DNA methylation status of RASAL2
promoter and identified two CpG sites
that are specifically methylated in luminal
B breast tumors, revealing an alterna-
tive mechanism of Ras activation
through epigenetic ablation of RASAL2
(Figure 1A). Notably, the DNA methyla-
tion patterns are significantly different
between luminal B and basal-like breast
tumors (Holm et al., 2010), with one
being the most and the other least
frequently methylated, respectively. As
little is known about themolecular mecha-
nisms that are responsible for the
suppression of RASAL2 via promoter
methylation, particularly in luminal B
breast cancer, more questions remain,
such as whether methylation of RASAL2
promoter CpG sites is a consequence of
generally elevated DNA methylation due
to enhanced activity of DNA methyltrans-
ferases in luminal B subtype or whether
RASAL2 is specifically targeted for
silencing to activate Ras/ERK signaling in
these tumors. The detailed contribution
of promoter methylation to the suppres-
sion of RASAL2 in breast cancer will be
interesting to further pursue. The evidence
shown by the authors provides an inter-
esting correlation between enhanced pro-
moter methylation and reduced RASAL2
mRNA levels, but it is still not clear if
other mechanisms for RASAL2 inactiva-
tion coexist in breast cancers. Indeed,
RasGAPs, exemplified by NF1 and
DAB2IP tumor suppressors, are suscepti-
ble to multiple ways of deregulation (Fig-
ures 1B and 1C), including epigenetic
silencing, proteasome-mediated degra-
dation, and loss-of-function mutations
(Bos et al., 2007; McGillicuddy et al.,
2009; Min et al., 2010). Understanding
the exact regulations of RASAL2
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Previewssuppression could shed light on new anti-
cancer strategies that inhibit the activation
of wild-type Ras by restoring expression
of the corresponding RasGAP.
Intriguingly, despite the fact that each
of the RasGAP members harbors a
conservedRasGAPdomain, not all exhibit
tumor suppressor functions (Min et al.,
2010). Accordingly, the existence of non-
Ras-associated functions of RasGAPs
has been proposed and further demon-
strated in the case of DAB2IP (Min et al.,
2010), which acts as a signaling scaffold
that coordinately regulates Ras and NF-
kB activation to promote tumor growth
and metastasis (Figure 1C), respectively.
Whether other conserved domain(s) be-
sides the RasGAP domain of RASAL2
also exert a Ras-independent tumor-sup-
pressive signaling cascade remains to be
investigated. Additionally, how the Ras-
GAPs coordinate with each other to regu-
late the activation of Ras in differenthuman cancers is not clear. Epigenetic
suppression of DAB2IP (Dote et al.,
2004) and the mutation of NF1 (The Can-
cer Genome Atlas Database) are also
observed in breast cancers, raising the
question of whether the deregulation
events of RasGAPs aremutually exclusive
or whether they coexist for sufficient
addiction to wild-type Ras activation in
breast cancer.REFERENCES
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Cancer cells display lysosome hypertrophy, secreting lysosomal hydrolases for tumor progression. Hyper-
trophy renders lysosomes fragile, increasing lysosomal membrane permeabilization (LMP) tendency. In
this issue of Cancer Cell, Petersen and colleagues show that lysosomal sphingomyelin content determines
LMP and cationic drugs displace acid sphingomyelinase from lysosomal membranes, increasing tumor
LMP and death.Early on after the discovery of lysosomes
by Christian de Duve as a separate com-
partment that confines highly destructive
hydrolases for the demolition and reuti-
lization of cellular substituents, the
concept that these structures might
alternatively represent ‘‘suicide bags’’
was proposed (de Duve, 1983). This led
to an intense search for lysosomatrophic
agents that might access this biology
for therapeutic purpose. Although a set
of lysosomal detergents with long hydro-
phobic tails and medium pK were defined
as capable of inducing lysosomal mem-brane permeabilization (LMP) and thereby
releasing the destructive power of hydro-
lases into the cytoplasm, this concept
was rapidly retired, because it was not
possible to assign lethal causality to
these compounds based on LMP as
opposed to postmortal lysosomal des-
truction (Miller et al., 1983).
In the interim, the field of cathepsin
protease biology developed. Cathepsins
represent a class of cysteine, serine, and
aspartate proteases that segregate into
lysosomes and, under homeostatic con-
ditions, serve to reutilize polypeptidesfor ongoing cellular metabolic require-
ments. Lysosomes contain more than
50 cathepsins, and, as a class, they
have been associated with various human
pathologies, including cancer. Numerous
cathepsins and other lysosomal enzymes,
e.g., heparanase, have been strongly
associated with cancer cell proliferation,
angiogenesis, and metastasis (Kallunki
et al., 2013). Evidence indicates that,
upon secretion, these tumor-promoting
lysosomal enzymes act extracellularly.
To accommodate this burgeoning need,
tumor cells in general display enlargementeptember 9, 2013 ª2013 Elsevier Inc. 279
